PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts. Show more
Location: 321 Harrison Avenue, Boston, MA, 02118, United States | Website: https://pepgen.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
337.5M
52 Wk Range
$0.88 - $9.77
Previous Close
$4.91
Open
$4.99
Volume
471,471
Day Range
$4.70 - $5.15
Enterprise Value
292.4M
Cash
74.65M
Avg Qtr Burn
-22.5M
Insider Ownership
0.13%
Institutional Own.
59.54%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PGN-EDODM1 Details Myotonic Dystrophy Type 1 (DM1) | Phase 2 Data readout | |
PGN-EDO51 Details Duchenne muscular dystrophy | Failed Discontinued |